PASSAGE BIO, INC. Research and Development Expense
PASSAGE BIO, INC. (PASG) reported Research and Development Expense of $3.34 million for the 3-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-03
- PASSAGE BIO, INC. research and development expense for the quarter ending 2026-06-30 was $3.34M, a 42.50% decline year-over-year.
- PASSAGE BIO, INC. research and development expense for the quarter ending 2026-03-31 was $4.09M, a 47.10% decline year-over-year.
- PASSAGE BIO, INC. research and development expense for the quarter ending 2025-12-31 was $5.42M, a 43.31% decline year-over-year.
- PASSAGE BIO, INC. research and development expense for the quarter ending 2025-09-30 was $4.31M, a 50.24% decline year-over-year.
- PASSAGE BIO, INC. research and development expense for fiscal 2023 was $61.42M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.34M S-4/A · filed 2026-09-03 | $7.44M S-4/A · filed 2026-09-03 | $12.85M derived: sum of 3 quarters · filed 2026-09-03 | $17.16M derived: sum of 4 quarters · filed 2026-09-03 |
| 2026-03-31 | $4.09M S-4 · filed 2026-07-21 | $9.51M derived: sum of 2 quarters · filed 2026-09-03 | $13.82M derived: sum of 3 quarters · filed 2026-09-03 | $19.63M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-12-31 | $5.42M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $9.72M derived: sum of 2 quarters · filed 2026-09-03 | $15.54M derived: sum of 3 quarters · filed 2026-09-03 | $23.28M S-4/A · filed 2026-09-03 |
| 2025-09-30 | $4.31M 10-Q · filed 2025-11-10 | $10.12M derived: sum of 2 quarters · filed 2026-09-03 | $17.86M 10-Q · filed 2025-11-10 | $27.42M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-06-30 | $5.81M S-4/A · filed 2026-09-03 | $13.55M S-4/A · filed 2026-09-03 | $23.11M derived: sum of 3 quarters · filed 2026-09-03 | $31.77M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-03-31 | $7.74M S-4 · filed 2026-07-21 | $17.30M derived: sum of 2 quarters · filed 2026-09-03 | $25.95M derived: sum of 3 quarters · filed 2026-09-03 | $36.38M derived: sum of 4 quarters · filed 2026-09-03 |
| 2024-12-31 | $9.56M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $18.21M derived: sum of 2 quarters · filed 2026-09-03 | $28.64M derived: sum of 3 quarters · filed 2026-09-03 | $40.18M S-4/A · filed 2026-09-03 |
| 2024-09-30 | $8.66M 10-Q · filed 2025-11-10 | $19.09M derived: sum of 2 quarters · filed 2025-11-10 | $30.62M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $10.43M 10-Q · filed 2025-08-12 | $21.96M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $11.54M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $61.42M 10-K · filed 2025-03-04 | |||
| 2020-03-31 | $13.12M 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $3.03M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |